Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Pfizer Inc
PFE
Alternate Symbol(s):
N.PFE
Healthcare
Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the...
Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its Oncology products include Ibrance, Xtandi, Inlyta, Bosulif, Lorbrena, Braftovi, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio and Tivdak. Its primary care products include Eliquis, Nurtec ODT/Vydura, Comirnaty, the Prevnar family, Abrysvo, FSME/IMMUN-TicoVac, Paxlovid and Lucira by Pfizer. Its specialty care products include Xeljanz, Enbrel (outside the U.S. and Canada), Inflectra, Cibinqo, Litfulo, Vyndaqel family, Genotropin, Sulperazon, Zavicefta, Medrol and Panzyga.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NYSE:PFE)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Apr 26, 2024 6:46am
New Press Release - U.S. FDA Approves Pfizer's BEQVEZ(TM) (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B
A one-time dose of BEQVEZ has reduced bleeds post-treatment compared to standard of care with a median of zero bleeds (range 0 to 19) after up to three years of follow-up, providing sustained bleed protection and potentially avoiding years of treatment burden with prophylaxis for many patients...
read article.
(394)
•••
barneyj44
X
View Profile
View Bullboard History
Comment by
barneyj44
on Apr 25, 2024 11:57pm
RE:The dividend of $0.42
Yeah Pfe has been a disaster. I'm done averaging down on this one. Seems there getting lawsuits thrown at them every second day.
Level Up Your Trading with BMO InvestorLine’s Enhanced Features
posted Nov 24, 2024 9:00am by
Bank of Montreal
-
|
Features like Multi-Leg Orders, Options Screener, and Strategy Builder will be particularly exciting for traders. They have been designed to be intuitive and user-friendly, regardless of your experience level. Whether you’re a seasoned pro or just starting out, you’ll find these tools easy to navigate and adapt to your investing style. ...read more
(174)
•••
ecolo101
X
View Profile
View Bullboard History
Post by
ecolo101
on Apr 25, 2024 5:08pm
The dividend of $0.42
Does not cover today's loss nothing else to add dyodd
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Apr 24, 2024 4:37pm
New Press Release - Pfizer Declares Second-Quarter 2024 Dividend
Board of Directors approves quarterly cash dividend of $0.42 per share Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.42 second-quarter 2024 dividend on the company’s common stock, payable June 14, 2024, to holders of the Common Stock of record at the close of...
read article.
(174)
•••
ecolo101
X
View Profile
View Bullboard History
Post by
ecolo101
on Apr 24, 2024 12:57pm
Last 6 months
From $31 to $26...can this boat be stabilized? hopefully R&D behind it will come up with something new and important for global health... it takes a lot of money in this business to survive long
...more
(174)
•••
ecolo101
X
View Profile
View Bullboard History
Post by
ecolo101
on Apr 22, 2024 4:05pm
The 50D SMA
Is $27.11 . Let's hope we cross It this week and walk on 200D SMA at $30.74. Then after we build on sounded ground toward $35. glta dyodd
(174)
•••
ecolo101
X
View Profile
View Bullboard History
Post by
ecolo101
on Apr 22, 2024 9:44am
Patience patience
When it will start going up it will be for the long run.....hopefully Q1 results later this week. Let's hope we see some clear indication... At least ex dividend date early in May. glta
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Apr 22, 2024 8:19am
New Press Release - European Commission Approves Pfizer's EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options
EMBLAVEO® is the first ß-lactam/ß-lactamase inhibitor antibiotic combination approved in the European Union for treating serious infections in adult patients caused by multidrug-resistant Gram-negative bacteria, including metallo-ß-lactamase-producing bacteriaEMBLAVEO® was reviewed under European...
read article.
(174)
•••
ecolo101
X
View Profile
View Bullboard History
Post by
ecolo101
on Apr 17, 2024 1:11pm
What is management doing?
I can't understand what is going on? Waiting for the next board meeting to discuss salary at their level? shareholders are not happy and afraid of no clear indication to the financial community
...more
(174)
•••
ecolo101
X
View Profile
View Bullboard History
Post by
ecolo101
on Apr 15, 2024 1:54pm
Resistance seems to be at $24
Not impossible to see lower number until we reach resistance. glta
(174)
•••
ecolo101
X
View Profile
View Bullboard History
Post by
ecolo101
on Apr 12, 2024 1:32pm
Now the $25
Ouc ouch ouch so frustrating, no mojo to come back up. not too many positive on this one. The bigger they get, they cut themselves from reality... analysts do not recommend it at all. dyodd
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Apr 11, 2024 10:05am
New Press Release - Pfizer Invites Shareholders to Attend Virtual-Only 2024 Annual Meeting of Shareholders on April 25
Pfizer Inc. (NYSE: PFE) announced today that its shareholders and the general public are invited to access its virtual-only 2024 Annual Meeting of Shareholders at 9:00 a.m. EDT on Thursday, April 25, 2024. Pfizer has designed the virtual Annual Meeting to ensure that its shareholders who attend...
read article.
(174)
•••
ecolo101
X
View Profile
View Bullboard History
Post by
ecolo101
on Apr 10, 2024 9:09am
From $60 to $26
And just stalling right there... and cruising in a tight bracket 26-28$ for how long? they have done so much money during the pandemic and now they have lot all interest from investors leaving
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Apr 09, 2024 6:45am
New Press Release - Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease
ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk. The vaccine was well-tolerated and demonstrated an immune response non-inferior to adults aged 60 years and olderPfizer intends to submit these findings to regulatory...
read article.
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >